Market Overview

Oppenheimer Raises Its Prognosis For The Medicines Company

Share:
Oppenheimer Raises Its Prognosis For The Medicines Company

The Medicines Company (NASDAQ: MDCO) announced Wednesday an agreement to sell its infectious disease business unit to Melinta Therapeutics, Inc. (NASDAQ: MLNT) for $270 million upfront. 

As part of the deal, Medicines Company would receive royalty payments of 5-25 percent on worldwide net sales of Vabomere, Orbactiv and Minocin.

The company said it plans to narrow its focus to inclisiran, transitioning to a pure-play R&D biotech company in the process. 

The Analyst

Oppenheimer analyst Jay Olson reviewed the development and upgraded his rating on the shares of Medicines Company from Perform to Outperform, with a 12-to-18-month price target of $50.

The Thesis

With the proposed sale, Medicines Company was able to generate non-dilutive funding for inclisiran development, Olson said in a Wednesday note. (See Olson's track record here.)

Inclisiran is an experimental cholestrol drug. 

The proceeds from the sale along with restructuring will provide enough cash to develop inclisiran up to NDA submission, planned for 2019, and no equity issuance is warranted at this time, Olson said.

"We believe PCSK9 market dynamics should improve with label inclusion of CV outcomes data creating potentially positive impact on guidelines and reimbursement," Olson said of the inclisiran opportunity. Inclisiran is well-differentiated and may enter a very different PCSK9 market by 2020, the analyst said. 

The Price Action

Medicines Company shares have been on a secular decline since early April, having lost about 11 percent year-to-date.

At the time of writing, the shares were rallying 2.77 percent to $31.

Related Links:

Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates

Medicines Company Gets FDA Approval, Has 119% Upside According To This Analyst

Photo courtesy of The Medicines Co.

Latest Ratings for MDCO

DateFirmActionFromTo
Oct 2019DowngradesBuyHold
Oct 2019MaintainsBuy
Sep 2019DowngradesBuyNeutral

View More Analyst Ratings for MDCO
View the Latest Analyst Ratings

Posted-In: Analyst Color M&A News Upgrades Health Care Price Target Analyst Ratings General Best of Benzinga

 

Related Articles (MDCO + MLNT)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
WENMorgan StanleyMaintains22.0
JAZZBernsteinReinstates150.0
XGNCantor FitzgeraldInitiates Coverage On18.0
LOOPRoth CapitalInitiates Coverage On14.0
SNABairdMaintains165.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

ICYMI: Apple Is Gaining Ground On Activated Smartphones In China

Tech ETFs And Stocks Tumble: Time To Buy?